Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
16 results
- AMBITIONIndependent statistical analysis of the AMBITION phase 3 trial of first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension, including time-to-event analysis, secondary endpoints, statistical methodology, safety, and interpretation.
- AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CIRTComplete statistical analysis of CIRT (NCT01594333), a randomized phase 3 trial of methotrexate versus placebo in cardiovascular disease, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, stratification, multiplicity, safety, and statistical…
- DAPA-MIIndependent statistical analysis of the DAPA-MI phase 3 trial of dapagliflozin versus placebo after acute myocardial infarction, including its hierarchical primary composite endpoint, win-ratio methodology, trial design, interpretation, and safety.
- E5103Independent statistical analysis of E5103 (NCT00433511), a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in breast cancer.
- EMPA-REG OUTCOMEComplete statistical analysis of EMPA-REG OUTCOME, the randomized phase 3 trial of empagliflozin in patients with type 2 diabetes mellitus, including its time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority framework, cardiovascular outcomes, microvascular…
- FOURIERIndependent statistical analysis of the FOURIER phase 3 trial of evolocumab versus placebo in subjects with elevated cardiovascular risk and dyslipidemia, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, and interpretation.
- GOLDEN-3Independent statistical analysis of GOLDEN-3 (NCT02347761), a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its FEV1 endpoint, MMRM methodology, multiplicity control, confidence intervals, and reported results.
- GOLDEN-4Independent statistical analysis of GOLDEN-4, a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its MMRM methodology, primary FEV1 results, multiplicity approach, safety data, and statistical interpretation.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- SUNLIGHTIndependent statistical analysis of the phase 3 SUNLIGHT trial of trifluridine/tipiracil with and without bevacizumab in refractory metastatic colorectal cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, and statistical interpretation.
- SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…
- SWITCH 2Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with type 2 diabetes, including hypoglycaemia, HbA1c, crossover design, non-inferiority, and…